scholarly journals Ethical issues in dementia

1996 ◽  
Vol 20 (2) ◽  
pp. 107-108 ◽  
Author(s):  
Alistair Burns ◽  
John Harris
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Ethical Issues ◽  
Ronald Reagan ◽  
Public Debate ◽  
Recent Meeting ◽  
The Media ◽  
The Subject ◽  
Scientific Advances

Public debate on dementia has intensified recently with scientific advances being scrutinised in the media, the genetics of Alzheimer's disease regularly portrayed as inextricably linked with the personal agony of whether to have ‘the test’ (which exists only for a small number of people) and the announcement by ex US President Ronald Reagan that he suffers from the disease. Several different areas provoke interest and speculation and this brief article attempts to highlight some, based on a recent meeting on the subject.

Destination memory in Alzheimer’s Disease: When I imagine telling Ronald Reagan about Paris

Cortex ◽  
2013 ◽  
Vol 49 (1) ◽  
pp. 82-89 ◽  
Author(s):  
Mohamad El Haj ◽  
Virginie Postal ◽  
Philippe Allain
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Ronald Reagan ◽  
Destination Memory

scholarly journals Working Memory and the Enactment Effect in Early Alzheimer’s Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Lara A. Charlesworth ◽  
Richard J. Allen ◽  
Suzannah Morson ◽  
Wendy K. Burn ◽  
Celine Souchay
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Working Memory ◽  
Free Recall ◽  
Older Adult ◽  
Memory Task ◽  
Enactment Effect ◽  
The Subject ◽  
Instruction Sequences ◽  
Early Alzheimer’S Disease

This study examines the enactment effect in early Alzheimer’s disease using a novel working memory task. Free recall of action-object instruction sequences was measured in individuals with Alzheimer’s disease (n=14) and older adult controls (n=15). Instruction sequences were read out loud by the experimenter (verbal-only task) or read by the experimenter and performed by the participants (subject-performed task). In both groups and for all sequence lengths, recall was superior in the subject-performed condition than the verbal-only condition. Individuals with Alzheimer’s disease showed a deficit in free recall of recently learned instruction sequences relative to older adult controls, yet both groups show a significant benefit from performing actions themselves at encoding. The subject-performed task shows promise as a tool to improve working memory in early Alzheimer’s disease.

Technological prospecting of music therapy in Alzheimer's disease

2021 ◽  
Vol 10 (16) ◽  
pp. e443101622316
Author(s):  
Murilo Bastos ◽  
Kelby Cavalheiro de Mendonça ◽  
Valquiria Camargo Lins ◽  
Eduardo Muzzolon ◽  
Deise Mara Soares ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Music Therapy ◽  
Memory Loss ◽  
Active Therapy ◽  
Pharmacological Interventions ◽  
Limited Efficacy ◽  
Drug Treatments ◽  
The Subject

Alzheimer's disease (AD) is characterized by cognitive impairment and progressive memory loss and drug treatments have limited efficacy. Thus, non-pharmacological interventions, such as music therapy, have shown to be promising as supporting pharmacological treatment and, therefore, may arouse commercial interest regarding the development of this type of product. Thus, this study aims to carry out a patentometric survey on patent registrations with music therapy in the treatment of AD. A systematic search was carried out from 2000 to 2020 on the Orbti-Questel website, searching for documents referring to music therapies in AD. The terms “Alzheimer music methodology active therapy” and “Alzheimer music methodology passive therapy” were used. After searching, reading, and excluding duplicate results, we found four patent families referring to music therapy in AD and all were selected as a result, which was considered little compared to the number of studies published on the subject.

IS A LARGE-SCALE SCREENING FOR ALZHEIMER’S DISEASE POSSIBLE? YES, IN A FEW YEARS

2019 ◽  
pp. 1-2
Author(s):  
F. Ribaldi ◽  
D. Altomare ◽  
G.B. Frisoni
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Large Scale ◽  
Task Force ◽  
Cost Effective ◽  
The European Union ◽  
New Era ◽  
Non Invasive ◽  
Recent Meeting ◽  
Large Scale Screening

Recent evidence on blood-based biomarkers is pointing the way towards a new era of large-scale, feasible, cost-effective and non-invasive screening for Alzheimer’s disease (AD). This was one of the main focuses of the recent meeting of the European Union-North American Clinical Trials in AD (EU/US CTAD) Task Force, which took place in Barcelona in October 24-27, 2018, and convened drug and diagnostics developers from industry and academia in order to define a roadmap for the development and marketing of blood-based biomarkers (1).

scholarly journals AI in the headlines: the portrayal of the ethical issues of artificial intelligence in the media

AI & Society ◽  
2020 ◽  
Vol 35 (4) ◽  
pp. 927-936 ◽  
Author(s):  
Leila Ouchchy ◽  
Allen Coin ◽  
Veljko Dubljević
Keyword(s):  
Artificial Intelligence ◽  
Media Coverage ◽  
Public Discourse ◽  
Ethical Issues ◽  
Public Debate ◽  
Daily Lives ◽  
Novel Technologies ◽  
Regulatory Frameworks ◽  
The Social ◽  
The Media

Abstract As artificial intelligence (AI) technologies become increasingly prominent in our daily lives, media coverage of the ethical considerations of these technologies has followed suit. Since previous research has shown that media coverage can drive public discourse about novel technologies, studying how the ethical issues of AI are portrayed in the media may lead to greater insight into the potential ramifications of this public discourse, particularly with regard to development and regulation of AI. This paper expands upon previous research by systematically analyzing and categorizing the media portrayal of the ethical issues of AI to better understand how media coverage of these issues may shape public debate about AI. Our results suggest that the media has a fairly realistic and practical focus in its coverage of the ethics of AI, but that the coverage is still shallow. A multifaceted approach to handling the social, ethical and policy issues of AI technology is needed, including increasing the accessibility of correct information to the public in the form of fact sheets and ethical value statements on trusted webpages (e.g., government agencies), collaboration and inclusion of ethics and AI experts in both research and public debate, and consistent government policies or regulatory frameworks for AI technology.

scholarly journals Action of anti-TNF-α drugs on the progression of Alzheimer's disease: A case report

2015 ◽  
Vol 9 (2) ◽  
pp. 196-200 ◽  
Author(s):  
Carlos Henrique Ferreira Camargo ◽  
Filipe Fernandes Justus ◽  
Giuliano Retzlaff ◽  
Marcelo Rezende Young Blood ◽  
Marcelo Derbli Schafranski
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Drug Class ◽  
Cognitive Response ◽  
Cognitive Improvement ◽  
Tnf Α ◽  
Patient Reported ◽  
Previously Treated ◽  
The Subject

The aim of this study was to describe a clinical case of a patient with Alzheimer's disease (AD) in use of an anti-TNF-α agent for rheumatoid arthritis (RA). The patient reported is an 81-year-old Caucasian man and retired teacher, diagnosed with RA in 2008 and AD in 2011. Treatment with donepezil was started in 2011 and the use of etanercept introduced in 2012. He was previously treated with adalimumab in 2010 for 18 months. In 2013, the subject was engaged in a clinical trial to assess a complementary non-pharmacological approach for AD, presenting significant cognitive improvement during the follow-up period. We propose the hypothesis of a synergistic effect of anti-TNF-α medication used for the treatment of RA as the cause of the improvement in cognitive response observed. These findings could suggest a possible use of this drug class in the therapeutic management of AD.

Ethical issues in Alzheimer’s disease: an overview

2012 ◽  
Vol 12 (5) ◽  
pp. 557-567 ◽  
Author(s):  
Antoine Leuzy ◽  
Serge Gauthier
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Ethical Issues
Sign in / Sign up

Export Citation Format

Share Document